Comparing a Low/No Warfarin Population versus Therapeutic in a Heartmate 3 Population

Purpose: The continuous-flow design of the Heartmate 3 (HM3) was developed to lower thrombosis risk compared to other left ventricular assist devices. Anticoagulation with warfarin remains the standard of care for further risk reduction. There is a lack of studies evaluating patients with HM3 off or at subtherapeutic warfarin levels. We aimed to review cases of patients with HM3 off warfarin or who have been consistently subtherapeutic and compare outcomes to similar patients consistently at therapeutic levels.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Source Type: research